查看文章

The availability of novel radionuclides plays a fundamental role in the development of personalized nuclear medicine. In particular, there is growing interest in pairs formed by two radioisotopes of the same element, the so-called true theranostic pairs, such as 61, 64 Cu/67 Cu, 43, 44 Sc/47 Sc and 155 Tb/149, 161 Tb. In this case, the two radionuclides have identical kinetics and chemical reactivity, allowing to predict whether the patient will benefit from a therapeutic treatment on the basis of nuclear imaging data. 47 Sc [t 1/2= 3.349 d, E β− m a x= 440.9 keV (68.4%); 600.3 keV (31.6%), E γ= 159.4 keV (68.3%)] is a promising radionuclide for theranostic applications in nuclear medicine. Its physical characteristics make it suitable for radionuclide therapy and allow SPECT imaging during treatment. Moreover, 47 Sc is foreseen as the therapeutic partner of the β+-emitters 43 Sc and 44 Sc, both under study for PET …